Schechter Investment Advisors LLC Grows Position in GSK plc (NYSE:GSK)

Schechter Investment Advisors LLC increased its holdings in shares of GSK plc (NYSE:GSK) by 15.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,320 shares of the pharmaceutical company’s stock after buying an additional 7,585 shares during the period. Schechter Investment Advisors LLC’s holdings in GSK were worth $1,939,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Indiana Trust & Investment Management Co raised its stake in GSK by 200.0% in the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after purchasing an additional 500 shares during the last quarter. Crews Bank & Trust acquired a new stake in shares of GSK in the 4th quarter worth $26,000. ST Germain D J Co. Inc. increased its stake in shares of GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 522 shares during the last quarter. Sunbelt Securities Inc. increased its stake in shares of GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after acquiring an additional 302 shares during the last quarter. Finally, Sierra Ocean LLC acquired a new stake in shares of GSK in the 4th quarter worth $32,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

Shares of GSK opened at $37.59 on Monday. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92. The stock has a market capitalization of $77.90 billion, a PE ratio of 23.64, a PEG ratio of 1.12 and a beta of 0.64. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The stock has a 50-day simple moving average of $34.99 and a 200-day simple moving average of $37.23.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, analysts predict that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. The ex-dividend date is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.18%. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is currently 98.74%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on GSK shares. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and cut their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Morgan Stanley started coverage on GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. Finally, StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven equities research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.